Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|RTOG-1308||RTOG||Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy For Inoperable Stage II-IIIB NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1806||SWOG||Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A151804||Alliance||Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0258||GOG||A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked; Advanced Endometrial Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1512||SWOG||A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-33||NSABP||A Randomized; Placebo-Controlled; Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3N0-1M0 Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy||Adult CIRB - Late Phase Emphasis||Completed|
|S1011||SWOG||A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-40502||CALGB||A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer<br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5181||ECOG-ACRIN||Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA4181||ECOG-ACRIN||A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|